Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
- PMID: 34051179
- DOI: 10.1016/S1470-2045(21)00284-9
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
Conflict of interest statement
SKP is a consultant for Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, Bristol Myers Squibb, Astellas Pharma, and GlaxoSmithKline; receives honoraria from Novartis, Medivaton, and Astellas Pharma; and receives funding from Eisai, Pfizer, Bristol Myers Squibb, Aveo, Nektar Therapeutics, Exelixis, and QED. PG has provided consulting to AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Dyania Health, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Heron Therapeutics, Immunomedics, Infinity Pharmaceuticals, Janssen, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics, Seattle Genetics, and 4D Pharma. PG's institution has received research funding from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Pfizer, and QED Therapeutics. ZBZ and LM declare no competing interests.
Comment on
-
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Similar articles
-
Chemoimmunotherapy in Metastatic Urothelial Carcinoma.Eur Urol. 2018 May;73(5):760-762. doi: 10.1016/j.eururo.2017.12.029. Epub 2018 Jan 10. Eur Urol. 2018. PMID: 29331216 No abstract available.
-
Re: Updates in the management and future landscape of urothelial carcinoma.J Oncol Pharm Pract. 2021 Mar;27(2):514-515. doi: 10.1177/1078155220980832. Epub 2020 Dec 22. J Oncol Pharm Pract. 2021. PMID: 33349147
-
Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.Eur Urol. 2018 Feb;73(2):153-155. doi: 10.1016/j.eururo.2017.09.012. Epub 2017 Sep 28. Eur Urol. 2018. PMID: 28967552 No abstract available.
-
Facing treatment of non-urothelial bladder cancers in the immunotherapy era.Crit Rev Oncol Hematol. 2020 Sep;153:103034. doi: 10.1016/j.critrevonc.2020.103034. Epub 2020 Jun 20. Crit Rev Oncol Hematol. 2020. PMID: 32622321 Review.
-
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.Urol Clin North Am. 2018 May;45(2):287-295. doi: 10.1016/j.ucl.2017.12.011. Urol Clin North Am. 2018. PMID: 29650143 Review.
Cited by
-
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.Nat Commun. 2022 Mar 28;13(1):1487. doi: 10.1038/s41467-022-29026-9. Nat Commun. 2022. PMID: 35347124 Free PMC article.
-
Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2.J Exp Clin Cancer Res. 2025 Mar 3;44(1):80. doi: 10.1186/s13046-025-03330-w. J Exp Clin Cancer Res. 2025. PMID: 40025525 Free PMC article.
-
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.Cancers (Basel). 2024 Sep 4;16(17):3071. doi: 10.3390/cancers16173071. Cancers (Basel). 2024. PMID: 39272928 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
